Research Paper Volume 16, Issue 11 pp 9692—9708

Figure 4. The impact of SETD2 dysfunction on immunotherapy response in melanoma. (A) Western blotting evaluated the protein level of SETD2, H3K36me3, K3K9me3, ATM, pATM, MSH2, MSH6, PMS2, and GADPH, respectively, in A375 cells cultured in EZM0414 at different concentrations. (B) TIDE score of TCGA-SKCM samples with different SETD2 mutation status (G1: TCGA-SKCM samples without SETD2 mutation; G2: TCGA-SKCM samples with SETD2 mutation). (C) The hazard ratio of clinical parameters including drug type, TMB, SETD2 mutation status, age, and sex for melanoma samples with immunotherapy from MSKCC database using Cox multivariate survival analysis. (D) The KM survival analysis of Cox hazards model using drug type, TMB, and SETD2 mutation status. (E) The ROC of Cox hazards model for predicting 1-year, 3-year, and 5-year survival. (F) Nomogram depicting the prognosis-predictive value of clinicopathological parameters and SETD2 status. (G) Calibration curves depicting the specificity and accuracy of the nomogram. *p < 0.05, **p < 0.01, ***p < 0.001.